RecruitingSleep ApneaChronic Nasal Congestion
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The addition of intranasal oxymetazoline for two weeks to already instituted optimal doses of intranasal fluticasone propionate will decrease the total number of obstructive apneas and hypopneas per hour of sleep in subjects with perennial allergic or non-allergic rhinitis and mild obstructive sleep apnea who have persistent nasal congestion despite maximum doses of NGCS.
Sponsor: University of South Florida
You may qualify if…
- ✓ 1. Male and female subjects 18 - 65 years of age.
- ✓ 2. At least a one year history of perennial allergic or non-allergic rhinitis.
- ✓ 3. Subjects must be on the maximum recommended doses of one of the following NGCS for at least one month. (See Table I)
- ✓ 4. AHI per hour of sleep \> 5 and \<15, minimum SpO2 88, indicating mild obstructive sleep apnea).
- ✓ 5. Average Nasal Congestion VAS of \> 3-10 indicating moderate to severe nasal congestion between visits 1 and 2 based on daily symptoms (average of 7 scores).
- ✓ 6. Average Congestion Quantifier 7 score of 7 between visits 1 and 2 based on weekly symptoms (average of 2 scores).
- ✓ 7. Willingness to participate as indicated by signed informed consent.
You may not qualify if…
- ✕ 1. Presence of hypersensitivity to oxymetazoline or fluticasone propionate.
- ✕ 2. Subjects receiving allergen immunotherapy but not on a stable maintenance regimen for at least 30 days before the first study visit.
- ✕ 3. If the subject has perennial allergic rhinitis, he/she should not be entered into this study eight weeks before, during, or six weeks after any seasonal exacerbation.
- ✕ 4. Women who are pregnant or lactating.
- ✕ 5. Other known nasal diseases likely to affect deposition of oxymetazoline such as sinusitis, nasal polyps, or major nasal structural malformations.
- ✕ 6. Respiratory tract infections in the last 14 days.
- ✕ 7. Infections requiring antibiotics in the last 14 days.
- ✕ 8. Asthma or chronic obstructive pulmonary disease (COPD) requiring roflumilast or more than the recommended doses of inhaled corticosteroids, beta agonists, or antimuscarinic agents.
Where it's recruiting
Florida
Tampa
Source: ClinicalTrials.gov · NCT02630121 · last updated 2025-01-24